Infectious Disease Point-of-Care Diagnostics Market Size, Share & Trends Analysis Report By Technology (Lateral Flow Immunoassay, Agglutination Test, Flow-through test/Immunoconcentration Assay, Molecular Diagnostics, Others), By Disease (Respiratory Infections, COVID-19, Influenza A/B, RSV, Others, Sexually Transmitted Infections), HIV (), Chlamydia (), Gonorrhea (), Syphilis (), Others (Vector-Borne Diseases, Hepatitis & Liver Diseases, Tuberculosis, Hospital-Acquired Infections, Others), By End Use (Hospitals & Clinics, Diagnostic Laboratories, Home Healthcare, Assisted Living Healthcare Facilities, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Infectious Disease Point-Of-Care Diagnostics Market Dynamics

Market Drivers

Growing Need for Antimicrobial Stewardship and Expansion of Decentralized Infectious Disease Testing Networks Drives Market

Increasing global focus on antimicrobial stewardship programs is accelerating adoption of infectious disease point-of-care diagnostics. Rapid pathogen identification helps clinicians differentiate bacterial from viral infections, reducing unnecessary antibiotic prescriptions and supporting targeted treatment decisions. The European Centre for Disease Prevention and Control reported in 2025 that antimicrobial resistance continues to cause more than 35,000 deaths annually across the European Union and European Economic Area, reinforcing the need for rapid diagnostic tools that enable evidence-based antimicrobial use, improved infection management outcomes, and sustained market growth.

The rapid expansion of decentralized healthcare delivery models is a major market driver for infectious disease point-of-care diagnostics. Healthcare systems are increasingly shifting diagnostic services from centralized laboratories to community clinics, pharmacies, urgent care centers, and mobile health units to improve testing accessibility and reduce result turnaround times. This is creating sustained demand for compact, rapid, and easy-to-operate diagnostic platforms capable of delivering accurate infectious disease results directly at the point of care across diverse healthcare environments globally.

Market Restraints

Specimen Quality Variability in Decentralized Testing and Maintaining Quality Control Outside Laboratory Infrastructure Restrain Market Expansion

Infectious disease point-of-care diagnostics frequently depend on specimens collected outside controlled laboratory environments, creating challenges related to sample quality and consistency. Variations in swab collection techniques, sample volume, storage conditions, and operator experience can affect diagnostic accuracy and result reliability. Since many point-of-care tests are used in pharmacies, community clinics, and remote healthcare settings, maintaining standardized specimen collection practices remains difficult, limiting confidence in test outcomes and restraining broader market adoption.

Unlike centralized laboratories that operate under tightly controlled quality management systems, point-of-care diagnostics are frequently deployed across pharmacies, physician offices, mobile clinics, and rural healthcare facilities. Ensuring routine calibration, quality control checks, operator competency, and compliance with testing protocols across thousands of decentralized locations remains challenging. Variability in operational practices can affect test reliability and increase oversight requirements, creating a significant restraint for large-scale deployment of infectious disease point-of-care diagnostic systems.

Market Opportunities

Integration into Community Pharmacy Testing and Development of Wastewater-Linked POC Surveillance Solutions Offer Growth Opportunities to Market Players

The expansion of pharmacist-led testing services is creating growth opportunity for infectious disease point-of-care diagnostics manufacturers. Community pharmacies are increasingly becoming frontline diagnostic access points for respiratory and seasonal infections, reducing pressure on hospitals and clinics. In 2025, the UK National Health Service expanded Pharmacy First services nationwide, enabling participating pharmacies to manage multiple common infectious conditions, supporting wider deployment of rapid near-patient diagnostic technologies across community healthcare settings.

Growing emphasis on localized outbreak monitoring is creating opportunities for point-of-care diagnostic systems integrated with environmental surveillance programs. Healthcare authorities increasingly seek rapid testing solutions that complement wastewater-based pathogen monitoring by providing immediate community-level infection confirmation. This approach supports faster outbreak containment, targeted public health interventions, and decentralized disease surveillance. Manufacturers capable of linking rapid diagnostics with real-time epidemiological monitoring frameworks can access emerging opportunities within public health preparedness and infectious disease response programs.

Market Challenges

Maintaining Diagnostic Performance and Balancing Rapid Turnaround Time with Laboratory-level Accuracy Challenges Market Growth

Maintaining consistent diagnostic accuracy against continuously evolving pathogens remains a major challenge in the infectious disease point-of-care diagnostics market. Genetic mutations can alter target sequences used in molecular and antigen-based tests, potentially affecting sensitivity and specificity. Manufacturers must frequently monitor emerging variants and update assay designs to sustain performance. This creates additional validation, regulatory, and manufacturing burdens while increasing development timelines and operational costs across the infectious disease diagnostics industry.

Healthcare providers increasingly expect point-of-care diagnostics to deliver results within minutes while maintaining accuracy comparable to centralized laboratory testing. Achieving both speed and high analytical performance remains technically challenging, particularly for low-pathogen-load infections and early-stage disease detection. Manufacturers must optimize assay chemistry, sample preparation, and device design without increasing complexity or cost. This constant trade-off between speed, sensitivity, and operational simplicity continues to challenge product development and market adoption.

Infectious Disease Point-of-Care Diagnostics Market Segmentation Analysis

By Technology

Based on technology, molecular diagnostics accounted for a share of 43.20% in 2025 due to rapid pathogen identification, superior analytical sensitivity for low microbial loads, and the ability to detect antimicrobial resistance markers directly from clinical specimens. These technologies support syndromic testing, reduce dependence on culture-based methods, and enable earlier evidence-based therapeutic interventions across acute care settings.

The lateral flow immunoassay segment is expected to grow at a CAGR of around 6.04% during the forecast period, owing to its instrument-free operation, suitability for community-based screening programs, and ability to deliver actionable results in resource-limited environments. Growing deployment in pharmacies, mobile health units, and outbreak response initiatives is further accelerating adoption across decentralized healthcare networks.

By Disease 

In 2025, respiratory infections accounted for a share of 69.85% in the infectious disease point-of-care diagnostics market, by disease. This is due to frequent seasonal outbreaks, overlapping clinical symptoms requiring rapid differentiation, and the need for immediate treatment and isolation decisions. High testing volumes across influenza, COVID-19, RSV, and other respiratory pathogens continue to support substantial diagnostic demand globally.

The hepatitis & liver diseases segment is expected to grow at a CAGR of 5.92% during the forecast period, driven by increasing emphasis on decentralized viral hepatitis screening, expansion of elimination programs, and rising utilization of near-patient diagnostic solutions in underserved regions. Early disease identification initiatives and linkage-to-care strategies are further supporting segment expansion.

By End Use

By end use, hospitals & clinics accounted for a share of 28.77% in 2025 due to high patient throughput, continuous demand for rapid infectious disease diagnosis, and integration of point-of-care testing into emergency and critical care workflows. These settings also benefit from trained personnel, established quality assurance systems, and broader access to advanced diagnostic technologies.

The home healthcare segment is expected to grow at a CAGR of 5.56% during the forecast period, driven by increasing availability of self-testing infectious disease kits, growing consumer preference for private testing, and advancements in digitally connected diagnostic devices. Rising awareness of early detection and remote health monitoring is further supporting adoption in home-based care environments.

Infectious Disease Point-of-Care Diagnostics Regional Outlook

North America Infectious Disease Point-of-Care Diagnostics Market

North America: Market Dominance Led by Highly Developed Infectious Disease Surveillance Systems and Expansion of Pharmacist-led Care Pathways

The North America infectious disease point-of-care diagnostics market accounted for the largest regional share of 43.68% in 2025, driven by extensive deployment of decentralized testing infrastructure across pharmacies, urgent care centers, retail clinics, and community healthcare facilities. The region also benefits from highly developed infectious disease surveillance systems that support rapid diagnostic adoption. In 2025, the US CDC's National Wastewater Surveillance System monitored thousands of testing sites nationwide, highlighting the increasing importance of real-time infectious disease detection and localized outbreak management capabilities.

US Infectious Disease Point-of-Care Diagnostics Market

The infectious disease point-of-care diagnostics market in US was valued at USD 4.76 billion in 2025, driven by growing utilization of point-of-care testing outside traditional hospital settings, enabling faster triage and treatment decisions. Expansion of pharmacist-led care pathways, urgent care networks, and community testing services has increased accessibility to infectious disease diagnostics. The ability to deliver rapid testing closer to patients supports healthcare system efficiency while reducing dependence on centralized laboratory infrastructure for routine infectious disease screening.

Canada Infectious Disease Point-of-Care Diagnostics Market

The infectious disease point-of-care diagnostics market in Canada was valued at USD 649.23 million in 2025. Healthcare authorities continue prioritizing decentralized healthcare delivery models to improve diagnostic accessibility in geographically dispersed regions. Point-of-care testing helps overcome logistical barriers associated with specimen transportation and delayed laboratory results. This approach enables earlier diagnosis, faster treatment initiation, and improved infectious disease management while supporting equitable healthcare access across underserved populations throughout the country.

Asia Pacific Infectious Disease Point-of-Care Diagnostics Market

Asia Pacific: Fastest Growth Driven by Increasing Investments in Community-level Disease Surveillance and Growing Adoption of Portable Diagnostic Technologies

The Asia Pacific infectious disease point-of-care diagnostics market is expected to grow at a CAGR of 6.14% during the forecast period, showcasing the fastest regional growth. Growth is supported by increasing investments in community-level disease surveillance, border health monitoring systems, and decentralized diagnostic infrastructure. Governments across the region are strengthening outbreak preparedness capabilities to address emerging infectious threats. Growing adoption of portable diagnostic technologies in primary healthcare settings is further accelerating demand for rapid infectious disease testing solutions.

China Infectious Disease Point-of-Care Diagnostics Market

The China infectious disease point-of-care diagnostics market was valued at USD 707.86 million in 2025. The country's healthcare modernization strategy emphasizes improving diagnostic accessibility beyond major urban centers through enhanced primary care networks. Growing deployment of rapid testing solutions in county hospitals and community health institutions is supporting earlier infectious disease detection. Domestic production capabilities are expanding availability of advanced point-of-care diagnostic technologies while reducing dependence on imported testing platforms.

India Infectious Disease Point-of-Care Diagnostics Market

The India infectious disease point-of-care diagnostics market was valued at USD 399.05 million in 2025. Government-led initiatives targeting tuberculosis, hepatitis, vector-borne diseases, and other infectious conditions are driving demand for rapid near-patient testing solutions. According to the Ministry of Health and Family Welfare, India screened more than 250 million individuals for tuberculosis under active case-finding initiatives during 2025, highlighting the growing importance of scalable point-of-care diagnostic technologies in large population-based disease detection programs.

Japan Infectious Disease Point-of-Care Diagnostics Market

The Japan infectious disease point-of-care diagnostics market was valued at USD 431.73 million in 2025, as the country's aging population creates a heightened need for early identification of respiratory and healthcare-associated infections among vulnerable patient groups. Point-of-care diagnostics enable faster clinical intervention and infection control measures without requiring extensive laboratory processing. Integration of advanced diagnostic technologies into elderly care pathways is contributing to growing utilization across healthcare and assisted-living environments.